We showed that a STING agonist induced the improved tumor growth inhibition of B16-F10 cells over 4T1 tumors; enhanced STING expression and activation in B16-F10 cells; intensified hematologic dysfunction in 4T1-bearing mice; and increased the systemic release of CCL2 in B16-F10 over 4T1-bearing mice. Here, STING1 is linked to neoplasm.